Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab in Chinese Adult Patients With Generalized Myasthenia Gravis (gMG)
NCT07596784Phase 3Recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2026
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ravulizumab in myasthenia gravis (MG), sponsored by Alexion Pharmaceuticals. Started Jul 2026; status: recruiting.
02
Drugs
ravulizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT07596784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07596784.